Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-03-24

FDA Approved: RELPAX — Supplemental Application (ROERIG)

View source ↗

Summary

FDA approves a supplemental application for RELPAX (eletriptan hydrobromide) submitted by ROERIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RELPAX (Eletriptan hydrobromide)

Snippet

SUPPL AP for RELPAX (ELETRIPTAN HYDROBROMIDE)